Market research
ASLN Aslan Pharmaceuticals Ltd ADR
NASDAQ USD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 72
- Dividend yield
- Not available
- Beta
- 1.4
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 72
- Dividend yield
- Not available
- Beta
- 1.4
About
About Aslan Pharmaceuticals Ltd ADR
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.
Research context
Aslan Pharmaceuticals Ltd ADR appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ASLN discussion.
5 years, 6 months ago
ASLAN Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 20.0% above its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.1.
ASLAN Pharmaceuticals Limited's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 37.1% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 75.3% to $-2M since the same quarter in the previous year.
Based on the above factors, ASLAN Pharmaceuticals Limited gets an overall score of 4/5.